Literature DB >> 6233

Disposition of (15,16-3H)naltrexone in the central nervous system of the rat.

A L Misra, R Bloch, J Vardy, S J Mulé, K Verebely.   

Abstract

After injection of (15,16-3H)naltrexone (10 mg/kg s.c.) in male Wistar rats, peak concentrations of drug occurred in brain and plasma within 0.5 hr. Levels of naltrexone were sustained in brain between 2 and 24 hr and were barely detectable at 48 hr. Significant amounts of metabolities were present in brain and plasma at longer time periods. The t1/2 of naltrexone in brain and plasma were approximately 8.0 and 11.4 hr. respectively. The brain/plasma ratios of naltrexone at earlier times (0.5-1 hr) were higher than those at later times. The binding of naltrexone in vitro with rat plasma proteins in concentrations of 1-10 mug/ml ranged between 41 and 59% 6beta-Naltrexol was present in very small amounts in brain but not in plasma. In addition to 7,8-dihydro-14-hydroxynormophinone and 7,8-dihydro-14-hydroxynormophine, tentative evidence was obtained for three other metabolites of naltrexone in brain. These metabolites were also present in plasma in addition to free and conjugated naltrexone and its N-dealkylated metabolites.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6233

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

1.  Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers.

Authors:  James W Cornish; David Henson; Sanford Levine; Joseph Volpicelli; Charles E Inturrisi; Byron C Yoburn; Charles P O'Brien
Journal:  Am J Addict       Date:  1993

Review 2.  Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

Authors:  R E Bullingham; H J McQuay; R A Moore
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

3.  The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models.

Authors:  Catherine F Moore; Omar A Protzuk; Bankole A Johnson; Wendy J Lynch
Journal:  Pharmacol Biochem Behav       Date:  2013-11-16       Impact factor: 3.533

4.  Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.

Authors:  Jun-Xu Li; Lance R McMahon; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2007-09-16       Impact factor: 4.530

5.  Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens.

Authors:  R A Gonzales; F Weiss
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

6.  Effects of naltrexone, and d-amphetamine, and their interaction on the stimulus control of choice behavior of rats.

Authors:  D M Grilly; G C Gowans
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavy-drinking rats.

Authors:  Carsten K Nielsen; Jeffrey A Simms; Haley B Pierson; Rui Li; Surendra K Saini; Subramaniam Ananthan; Selena E Bartlett
Journal:  Biol Psychiatry       Date:  2008-09-06       Impact factor: 13.382

8.  Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin.

Authors:  Marissa J Metz; Caitlin M Daimon; Shane T Hentges
Journal:  eNeuro       Date:  2021-06-16

9.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

10.  Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood.

Authors:  Waleed O Farid; Andrew J Lawrence; Elena V Krstew; Robert J Tait; Gary K Hulse; Sarah A Dunlop
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.